| P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
| P17 | country | United States of America | Q30 |
| P582 | end time | 2010-05-01 | |
| P1050 | medical condition | chronic idiopathic myelofibrosis | Q3857106 |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 27 | |
| P8005 | research subject recruitment status | completed | Q76651189 |
| P859 | sponsor | The University of Texas MD Anderson Cancer Center | Q1525831 |
| P580 | start time | 2007-06-01 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis | |